“Yes, we have suspended it from the PQ (prequalification list),” spokesman Tarik Jasarevic said in an emailed response to .. “The suspension is a signal to countries that the WHO, in accordance with treatment guidelines, does not recommend that countries purchase the COVID drug.”
Jasarevic added that the WHO was not aware that any international buyer was supplying the drug to low- and middle-income countries.
“We regret that the WHO recommendations do not take this data into account at a time when the number of new cases is increasing significantly around the world and doctors are using Veklury, the first and only authorized treatment against COVID- 19 in more than 50 countries around the world, “Gilead reacted in a statement.
Remdesivir was initially developed against Ebola hemorrhagic fever and is sold by the Gilead laboratory under the trade name Veklury.
On July 3, it became the first COVID-19 drug to receive a conditional sales authorization on the European market. However, it is generating more enthusiasm in North America than in the Old Continent.
In France, the health authority considered that his interest (or “medical service provided”) is “low”.
For its part, the European Medicines Agency indicated on October 2 that it was going to study reports that the medicine causes “acute kidney problems.”
The WHO has been recommending the use of dexamethasone, a very affordable corticosteroid on the international market, for the treatment of severe cases of COVID-19 for months, since it has been the one that has offered the best results to date.
With information from ., . and .